×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SUPN – supernus pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SUPN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
04:30 pm
supn
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Medium
Report
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
11/6
06:13 am
supn
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/5
08:04 am
supn
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/4
09:57 pm
supn
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Medium
Report
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
11/4
08:58 pm
supn
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates [Yahoo! Finance]
11/4
04:05 pm
supn
Supernus Announces Third Quarter 2024 Financial Results
Medium
Report
Supernus Announces Third Quarter 2024 Financial Results
10/31
04:14 pm
supn
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 [Yahoo! Finance]
Low
Report
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 [Yahoo! Finance]
10/31
04:10 pm
supn
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Low
Report
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
04:05 pm
SUPN
supernus pharmaceuticals, inc.
BEAT
Report
0.1%
supernus pharmaceuticals, inc.
8/6/2024
04:06 pm
SUPN
supernus pharmaceuticals, inc.
BEAT
Report
14.5%
supernus pharmaceuticals, inc.
5/8/2024
04:05 pm
SUPN
supernus pharmaceuticals, inc.
MISS
Report
-4.2%
supernus pharmaceuticals, inc.
2/27/2024
04:05 pm
SUPN
supernus pharmaceuticals, inc.
MISS
Report
1.3%
supernus pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:15 pm
supn
Form SC 13G/A SUPERNUS PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A SUPERNUS PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
11/12
04:16 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 11 Filed by: NEWHALL CHARLES W III
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 11 Filed by: NEWHALL CHARLES W III
11/12
04:15 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: Hudson Frederick M.
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: Hudson Frederick M.
11/12
04:13 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: GEMAYEL GEORGES
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: GEMAYEL GEORGES
11/12
04:12 pm
supn
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: Khattar Jack A.
Low
Report
Form 4 SUPERNUS PHARMACEUTICALS For: Nov 08 Filed by: Khattar Jack A.
11/12
09:32 am
supn
Form 144 SUPERNUS PHARMACEUTICALS Filed by: NEWHALL CHARLES W III
Low
Report
Form 144 SUPERNUS PHARMACEUTICALS Filed by: NEWHALL CHARLES W III
11/8
05:00 pm
supn
Form 144 SUPERNUS PHARMACEUTICALS Filed by: Khattar Jack A.
Low
Report
Form 144 SUPERNUS PHARMACEUTICALS Filed by: Khattar Jack A.
11/8
04:36 pm
supn
Form 144 SUPERNUS PHARMACEUTICALS Filed by: Hudson Frederick M.
Low
Report
Form 144 SUPERNUS PHARMACEUTICALS Filed by: Hudson Frederick M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Supernus to Acquire CNS Portfolio from US WorldMeds
19.0%
3/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.8%
11/7 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 6.1%
4/3 Form 8-K SUPERNUS PHARMACEUTICALS For: Mar 30 5.7%
11/8 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating. 5.1%
8/27 Form 4 SUPERNUS PHARMACEUTICALS For: Aug 23 Filed by: Khattar Jack A. 5.1%
3/30 Supernus Provides Business Update 4.8%
3/4 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.4%
6/25 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.0%
4/24 Supernus to Host First Quarter Results Earnings Conference Call 3.3%
3/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.8%
11/7 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 6.1%
4/3 Form 8-K SUPERNUS PHARMACEUTICALS For: Mar 30 5.7%
11/8 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating. 5.1%
8/27 Form 4 SUPERNUS PHARMACEUTICALS For: Aug 23 Filed by: Khattar Jack A. 5.1%
3/30 Supernus Provides Business Update 4.8%
3/4 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.4%
6/25 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.0%
4/24 Supernus to Host First Quarter Results Earnings Conference Call 3.3%
TOP News Decliners
11/5
Q3/2019 9/30/2019 EPS 0.540 ZacksConsensus 0.590 ActVsEst (0.050) - Miss
-31.6%
8/6 Q2/2019 6/30/2019 EPS 0.610 ZacksConsensus 0.560 ActVsEst 0.050 - Beat -15.0%
2/25 Supernus Announces Fourth Quarter and Full Year 2019 Financial Results -14.9%
2/26 Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool] -7.8%
8/27 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.0%
5/7 Form 8-K SUPERNUS PHARMACEUTICALS For: May 07 -3.5%
5/29 Supernus to Present at the Jefferies 2019 Global Healthcare Conference -3.5%
9/25 Form 8-K SUPERNUS PHARMACEUTICALS For: Sep 25 -3.4%
1/23 Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 21 -2.6%
4/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) had its price target raised by analysts at Piper Sandler from $17.00 to $25.00. They now have a "neutral" rating on the stock. -2.5%
8/6 Q2/2019 6/30/2019 EPS 0.610 ZacksConsensus 0.560 ActVsEst 0.050 - Beat -15.0%
2/25 Supernus Announces Fourth Quarter and Full Year 2019 Financial Results -14.9%
2/26 Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool] -7.8%
8/27 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.0%
5/7 Form 8-K SUPERNUS PHARMACEUTICALS For: May 07 -3.5%
5/29 Supernus to Present at the Jefferies 2019 Global Healthcare Conference -3.5%
9/25 Form 8-K SUPERNUS PHARMACEUTICALS For: Sep 25 -3.4%
1/23 Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 21 -2.6%
4/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) had its price target raised by analysts at Piper Sandler from $17.00 to $25.00. They now have a "neutral" rating on the stock. -2.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: